Vista, CA, United States of America

Vivek K Rajwanshi

USPTO Granted Patents = 5 


Average Co-Inventor Count = 10.3

ph-index = 5

Forward Citations = 468(Granted Patents)


Company Filing History:


Years Active: 2007-2010

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Innovations of Vivek K Rajwanshi

Introduction

Vivek K Rajwanshi is a notable inventor based in Vista, California. He has made significant contributions to the field of pharmaceuticals, particularly in the development of nucleotide mimics and therapeutic agents. With a total of five patents to his name, his work has the potential to impact the treatment of various diseases.

Latest Patents

Rajwanshi's latest patents include "Nucleotide mimics and their prodrugs" and "Tricyclic nucleosides or nucleotides as therapeutic agents." The first patent focuses on nucleoside diphosphate and triphosphate mimics, which are designed to be used as antiviral, antimicrobial, and anticancer agents. These compounds can be formulated as pharmaceutically acceptable salts or prodrugs, providing methods for treating viral infections and proliferative disorders. The second patent highlights the utility of nucleosides and nucleotides containing a tricyclic base for treating infectious diseases and cancer.

Career Highlights

Throughout his career, Rajwanshi has worked with companies such as Biota Scientific Management Pty Ltd and Biota, Inc. His experience in these organizations has contributed to his expertise in pharmaceutical innovations.

Collaborations

Rajwanshi has collaborated with notable professionals in his field, including Phillip Dan Cook and Marija Prhavc. These collaborations have likely enhanced his research and development efforts.

Conclusion

Vivek K Rajwanshi is a distinguished inventor whose work in nucleotide mimics and therapeutic agents holds promise for advancing medical treatments. His contributions to the field are noteworthy and reflect his commitment to innovation.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…